Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue 5, 2011, Pages 594-605

  Gandini, Mariana ^a   Reis, Sonia Regina Nogueira Ignacio ^a   Torrentes Carvalho, Amanda ^a   Azeredo, Elzinandes Leal ^a   da Silva Freire, Marcos ^b   Galler, Ricardo ^b   Kubelka, Claire Fernandes ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

Cytokines; Dendritic cells; Dengue virus; Flavivirus; Yellow fever vaccine

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; DENGUE VACCINE; TUMOR NECROSIS FACTOR ALPHA; YELLOW FEVER VACCINE;

ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; DENDRITIC CELL; DENGUE; DENGUE VIRUS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; SECRETION; VIROLOGY; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; INTERFERON-ALPHA; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

DENGUE VIRUS; FLAVIVIRUS; YELLOW FEVER VIRUS;

EID: 80052703435     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000500012     Document Type: Article

References (78)

1. Ahmad SM, Haskell MJ, Raqib R, Stephensen CB 2008. Men with low vitamin A stores respond adequately to primary yellow fever and secondary tetanus toxoid vaccination. J nutr 138: 2276-2283.
2. + dendritic cells. Nat Immunol 1: 83-87.
3. Assuncao-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, Pacheco P, Barbosa-Lima G, Gomes RN, Bozza PT, Da Poian AT, Teixeira MM, Bozza MT 2010. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 24: 218-228.
4. Azeredo EL, Zagne SM, Santiago MA, Gouvea AS, Santana AA, Neves-Souza PC, Nogueira RM, Miagostovich MP, Kubelka CF 2001. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology 204: 494-507.
5. Bae HG, Domingo C, Tenorio A, de Ory F, Munoz J, Weber P, Teuwen DE, Niedrig M 2008. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 197: 1577-1584.
6. Barba-Spaeth G, Longman RS, Albert ML, Rice CM 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202: 1179-1184.
7. Blanco P, Palucka AK, Pascual V, Banchereau J 2008. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19: 41-52.
8. Blazquez AB, Berin MC 2008. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. J Immunol 180: 4441-4450.
9. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza PT, Kubelka CF 2008. Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8: 86.
10. Braga ELA, Moura P, Pinto LMO, Ignacio SRN, Oliveira MJC, Cordeiro MT, Kubelka CF 2001. Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferongamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem Inst Oswaldo Cruz 96: 229-232.
11. Caufour PS, Motta MC, Yamamura AM, Vazquez S, Ferreira I, Jabor AV, Bonaldo MC, Freire MS, Galler R 2001. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 79: 1-14.
12. Chakravarti A, Kumaria R 2006. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J Med Res 123: 25-30.
13. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS 2000. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 28: 183-188.
14. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM 2006. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 74: 142-147.
15. Chen RF, Liu JW, Yeh WT, Wang L, Chang JC, Yu HR, Cheng JT Yang 2005. Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 44: 43-50.
16. Clark IA 2007. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 18: 335-343.
17. Clyde K, Kyle JL, Harris E 2006. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 80: 11418-11431.
18. Deauvieau F, Sanchez V, Balas C, Kennel A, Dem A, Lang J, Guy B 2007. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am J Trop Med Hyg 76: 144-154.
19. + T cells into high IL-4-producing effectors. Int Arch Allergy Immunol 118: 384-386.
20. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E 2000. Modulation of dengue virus infection in human cells by alpha, beta and gamma interferons. J Virol 74: 4957-4966.
21. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G 2010. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 107: 16922-16927.
22. Fedele G, Frasca L, Palazzo R, Ferrero E, Malavasi F, Ausiello CM 2004. CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol 34: 1342-1350.
23. Fink J, Gu F, Ling L, Tolfvenstam T, Olfat F, Chin KC, Aw P, George J, Kuznetsov VA, Schreiber M, Vasudevan SG, Hibberd ML 2007. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis 1: e86.
24. Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T, Malavasi F, Ausiello CM 2006. CD38 orchestrates migration, survival and Th1 immune response of human mature dendritic cells. Blood 107: 2392-2399.
25. Galler R, Marchevsky RS, Caride E, Almeida LF, Yamamura AM, Jabor AV, Motta MC, Bonaldo MC, Coutinho ES, Freire MS 2005. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for Rhesus monkeys. Braz J Med Biol Res 38: 1835-1846.
26. Geisbert TW, Jahrling PB 2004. Exotic emerging viral diseases: progress and challenges. Nat Med 10: S110-121.
27. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Rothman AL, Ennis FA 999. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 59: 329-334.
28. Gubler DJ 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21th century. Trends Microbiol 10: 100-103.
29. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J 2010. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-649.
30. Hacker UT, Jelinek T, Erhardt S, Eigler A, Hartmann G, Nothdurft HD, Endres S 1998. In vivo synthesis of tumor necrosis factoralpha in healthy humans after live yellow fever vaccination. J Infect Dis 177: 774-778.
31. Halstead SB 2007. Dengue. Lancet 370: 1644-1652.
32. Ho LJ, Shaio MF, Chang DM, Liao CL, Lai JH 2004. Infection of human dendritic cells by dengue virus activates and primes T cells towards Th0-like phenotype producing both Th1 and Th2 cytokines. Immunol Invest 33: 423-437.
33. Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, Imbert P, Pecarere JL, Vergez-Pascal R, Wattre P 1993. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48: 324-331.
34. Jenkins SJ, Perona-Wright G, Worsley AG, Ishii N, MacDonald AS 2007. Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo. J Immunol 179: 3515-3523.
35. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 79: 5414-5420.
36. Khaiboullina SF, Rizvanov AA, Holbrook MR, St Jeor S 2005. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 342: 167-176.
37. Kubelka CF, Borges PA, VonSydow FF, Farid FO, Lampe E 1995. Analysis of tumor necrosis factor-alpha serum level in Brazilian patients with dengue-2. Mem Inst Oswaldo Cruz 90: 741-742.
38. Lanzavecchia A, Sallusto F 2004. Lead and follow: the dance of the dendritic cell and T cell. Nat Immunol 5: 1201-1202.
39. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, Tung YC, Lin YS, Yeh TM, Chen SH, Liu HS 2006. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 87: 3623-3630.
40. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I de C, Ramos C, Rico-Hesse R 1999. Dengue virus structural differences that correlate with pathogenesis. J Virol 73: 4738-4747.
41. Levy A, Valero N, Espina LM, Anez G, Arias J, Mosquera J 2009. Increment of interleukin 6, tumour necrosis factor alpha, nitric oxide, C-reactive protein and apoptosis in dengue. Trans R Soc Trop Med Hyg 104: 16-23.
42. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA 2001. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 75: 3501-3508.
43. Martins MA, Silva ML, Eloi-Santos SM, Ribeiro JG, Peruhype-Magalhaes V, Marciano AP, Homma A, Kroon EG, Teixeira- Carvalho A, Martins-Filho OA 2008. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 26: 1173-1184.
44. Miagostovich MP, Nogueira RM, Cavalcanti SM, Marzochi KB, Schatzmayr HG 1993. Dengue epidemic in the state of Rio de Janeiro, Brazil: virological and epidemiological aspects. Rev Inst Med Trop Sao Paulo 35: 149-154.
45. Monath TP 2001. Yellow fever: an update. Lancet Infect Dis 1: 11-20.
46. Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC 2001. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 30: 229-233.
47. Neves-Souza PC, Azeredo EL, Zagne SM, Valls-de-Souza R, Reis SR, Cerqueira DI Nogueira RM, Kubelka CF 2005. Inducible nitric oxide synthase (iNOS) expression in monocytes during acute dengue fever in patients and during in vitro infection. BMC Infect Dis 5: 64.
48. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, Lin CF, Yeh TM, Do QH, Vu TQ, Chen LC, Huang JH, Lam TM, Liu CC, Halstead SB 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 189: 221-232.
49. Nightingale ZD, Patkar C, Rothman AL 2008. Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. J Leuk Biol 84: 1028-1038.
50. Noisakran S, Perng GC 2008. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp Biol Med (Maywood) 233: 401-408.
51. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G 1997. Expression and function of OX40 ligand on human dendritic cells. J Immunol 159: 3838-3848.
52. +) T cells into high IL-4-producing effectors. Blood 92: 3338-3345.
53. Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, Barvir D, Gunther V, Burgess T, Kohno Y, Padmanabhan R, Sun W 2007. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88: 148-156.
54. Post PR, Santos CND, Carvalho R, Lopes OS, Galler R 1991. Molecular analysis of yellow fever virus 17DD vaccine strain. Mem Inst Oswaldo Cruz 86: 239-246.
55. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Zhu H, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P Jr, Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, del Rio C, Altman J, Ahmed R 2008. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198: 500-507.
56. Quah BJ, O'Neill HC 2005. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 9: 643-654.
57. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8 and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424.
58. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
59. Reis SRNI, Sampaio ALF, Henriques MGM, Gandini M, Azeredo EL, Kubelka CF 2007. An in vitro model for dengue virus infection that exhibits human monocyte infection, multiple cytokine production and dexamethasone immunomodulation. Mem Inst Oswaldo Cruz 102: 983-990.
60. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A 2010. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84: 4845-4850.
61. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O 1994. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 169: 807-813.
62. Sabatte J, Maggini J, Nahmod K, Amaral MM, Martinez D, Salamone G, Ceballos A, Giordano M, Vermeulen M, Geffner J 2007. Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function. Cytokine Growth Factor Rev 18: 5-17.
63. Scherer CA, Magness CL, Steiger KV, Poitinger ND, Caputo CM, Miner DG, Winokur PL, Klinzman D, McKee J, Pilar C, Ward PA, Gillham MH, Haulman NJ, Stapleton JT, Iadonato SP 2007. Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus or upper respiratory infections. Vaccine 25: 6458-6473.
64. Schnittler HJ, Feldmann H 2003. Viral hemorrhagic fever - a vascular disease? Thromb Haemost 89: 967-972.
65. Silva ML, Espirito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, de Andrade Maranhao-Filho P, Auxiliadora-Martins M, de Menezes Martins R, Galler R, da Silva Freire M, Marcovistz R, Homma A, Teuwen DE, Eloi-Santos SM, Andrade MC, Teixeira-Carvalho A, Martins-Filho OA 2010. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 17: 118-126.
66. Silva ML, Martins MA, Espirito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, Homma A, Kroon EG, Teixeira-Carvalho A, Eloi-Santos SM, Martins-Filho OA 2011. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29: 583-592.
67. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, Dung NT, Long TH, Hoang DM, Chau NV, Thao le TT, Hien TT, Relman DA, Farrar J 2007. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 195: 1097-1107.
68. Srikiatkhachorn A 2009. Plasma leakage in dengue haemorrhagic fever. Thromb Haemost 102: 1042-1049.
69. Srikiatkhachorn A, Green S 2010. Markers of dengue disease severity. Curr Top Microbiol Immunol 338: 67-82.
70. Steinman RM, Nussenzweig MC 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99: 351-358.
71. Suharti C, van Gorp EC, Setiati TE, Dolmans WM, Djokomoeljanto RJ, Hack CE, ten CH, van der Meer JW 2002. The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 87: 42-46.
72. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, Liang Z, Subramanian H, Porter KR, Sun W, Burgess TH 2009. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383: 207.
73. Thomsen AR, Nansen A, Madsen AN, Bartholdy C, Christensen JP 2003. Regulation of T cell migration during viral infection: role of adhesion molecules and chemokines. Immunology Lett 85: 119-127.
74. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodigues SG, Laval C, Costa ZG, Vilela MF, Santos CL, Papaiordanou PM, Alves VA, Andrade LD, Sato HK, Rosa ES, Froguas GB, Lacava E, Almeida LM, Cruz AC, Rocco IM, Santos RT, Oliva OF 2001. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91-97.
75. Wallet MA, Sen P, Tisch R 2005. Immunoregulation of dendritic cells. Clin Med Res 3: 166-175.
76. Woodson SE, Freiberg AN, Holbrook MR 2011. Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology 412: 188-195.
77. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6: 816-820.
78. Youn S, Cho H, Fremont DH, Diamond MS 2010. A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition. J Virol 84: 9516-9532.